Journal Article
. 2019 Nov;26(1).
doi: 10.1158/1078-0432.CCR-19-2424.

Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer

Fei Wang 1 Sonya Reid 2 Wei Zheng 1 Tuya Pal 3 Ingrid Meszoely 4 Ingrid A Mayer 2 Christina E Bailey 4 Ben Ho Park 2 Xiao-Ou Shu 5 
Affiliations
  • PMID: 31748278
  •     22 References

Abstract

Purpose: Prognostic value of Oncotype DX Breast Recurrence Score (RS) in male patients with breast cancer is understudied. We evaluated associations of RS with overall mortality in male patients with breast cancer and compared it with female counterparts.

Experimental Design: With a cohort of 848 male and 110,898 female patients with breast cancer identified from the National Cancer Database (2010-2014), we estimated HRs and 95% confidence intervals (CI) for overall mortality associated with RS using Cox regression models. RS was evaluated continuously, as well as by categorization following respective traditional (≤17, 18-30, and ≥31) and TAILORx (≤10, 11-25, and ≥26) cutoffs.

Results: RS was positively associated with mortality in male patients (HR = 1.13; 95% CI, 1.02-1.26 per unit RS increment) up to RS > 21, after which the risk plateaued. Among female patients, mortality began to increase with RS only when RS > 23 (HR = 1.02; 95% CI, 1.01-1.02 per unit of RS increment). The intermediate- (HR = 5.37; 95% CI, 1.79-16.11) and high-risk diseases (HR = 4.28; 95% CI, 1.22-14.97) defined by TAILORx, but not traditional cutoffs established for female patients, were associated with elevated mortality risk in men even after adjustment for demographic, clinical characteristics, and treatments, except chemotherapy.

Conclusions: RS is associated with mortality in male patients with breast cancer at a much lower threshold than that for female patients. Studies are needed to establish specific guidelines for RS thresholds for male patients with breast cancer.

Male breast cancer: management and follow-up recommendations.
John V Kiluk, Marie Catherine Lee, +5 authors, Christine Laronga.
Breast J, 2011 Sep 03; 17(5). PMID: 21883641
The 21-Gene Recurrence Score in Male Breast Cancer.
Gulisa Turashvili, Monica Gonzalez-Loperena, +4 authors, Hannah Y Wen.
Ann Surg Oncol, 2018 Mar 10; 25(6). PMID: 29520654    Free PMC article.
Male breast cancer is not congruent with the female disease.
Ian S Fentiman.
Crit Rev Oncol Hematol, 2016 Mar 19; 101. PMID: 26989051
Review.
Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2019 Jan 09; 69(1). PMID: 30620402
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Breast Cancer in Men.
Sharon H Giordano.
N Engl J Med, 2018 Jun 14; 378(24). PMID: 29897847
Highly Cited. Review.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2018 Nov 06; 125(2). PMID: 30387876    Free PMC article.
Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.
Sriram Venigalla, Ruben Carmona, +4 authors, Jacob E Shabason.
JAMA Oncol, 2018 May 26; 4(10). PMID: 29800030    Free PMC article.
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
Molecular Characterization and Mortality From Breast Cancer in Men.
Suleiman Alfred Massarweh, George W Sledge, +3 authors, Steven Shak.
J Clin Oncol, 2018 Mar 28; 36(14). PMID: 29584547    Free PMC article.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Male breast cancer: genetics, epigenetics, and ethical aspects.
P Rizzolo, V Silvestri, +6 authors, L Ottini.
Ann Oncol, 2013 Oct 30; 24 Suppl 8. PMID: 24131976
Review.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Fabrice Andre, Nofisat Ismaila, +10 authors, Vered Stearns.
J Clin Oncol, 2019 Jun 01; 37(22). PMID: 31150316
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Mary Pritzlaff, Pia Summerour, +8 authors, Holly LaDuca.
Breast Cancer Res Treat, 2016 Dec 23; 161(3). PMID: 28008555    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Incidence and outcome of male breast cancer: an international population-based study.
Hui Miao, Helena M Verkooijen, +6 authors, Mikael Hartman.
J Clin Oncol, 2011 Oct 05; 29(33). PMID: 21969512
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
Ariella M Altman, Scott Kizy, +5 authors, Schelomo Marmor.
Ann Surg Oncol, 2018 Jun 17; 25(8). PMID: 29907942